Direct comparisons of effectiveness and safety of treatment with Apixaban, Dabigatran and rivaroxaban in atrial fibrillation
Direct oral anticoagulants (DOACs) have been proven non-inferior or superior to warfarin in preventing stroke and systemic embolism, with a lower risk of major hemorrhage, in patients with non-valvular atrial fibrillation (NVAF). We sought to investigate whether effectiveness and safety differs among apixaban, rivaroxaban and dabigatran.
Source: Thrombosis Research - Category: Hematology Authors: M. Jansson, S. Sj älander, V. Sjögren, H. Renlund, B. Norrving, A. Själander Tags: Full Length Article Source Type: research
More News: Atrial Fibrillation | Coumadin | Hematology | Hemorrhagic Stroke | Pradaxa | Stroke | Thrombosis | Warfarin